Following weight changes in adults with severe obesity treated with semaglutide in France
Follows weight and well-being in adults with severe obesity treated with semaglutide.
Plain-language title generated from the registry record
Registry title: Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
Key facts
- Where
- Nantes, FranceSee the site
Where in France
- Nantes University HospitalNantes, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nantes University Hospital
- Trial code
- NCT07423481
- Record updated
- 18 September 2026
- Original description
SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.Read full original descriptionShow less
SEMAFOLLOW - Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity: Observational, National Cohort, Real-world Study in France
SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.
Inclusion: Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY; No objection to the use of their data; Patients able to complete an online questionnaire (via the internet).
Exclusion: Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection.